Patients with colon cancer have learned over the last two years that we have now a genetic marker which can predict efficacy of antibodies against EGFR which are used in patients with metastatic colon cancer.
We have learned that tumors with mutations in KRAS will not benefit from this treatment. All patients should be tested for KRAS mutation if they have advanced or metastatic disease.
However patients who have mutations of the KRAS gene don’t do worse than patients with wild type. The only difference is that the drugs which target EGFR will not work. Read the rest of this entry »